Isotechnika partner nears end of patient recruitment

Isotechnika Pharma (TSX:ISA) said its partner, Lux Biosciences, expects to complete patient recruitment of its continuing Phase 3 trial of Luveniq (voclosporin) in North America for the treatment of non-infectious uveitis in early 2012. Lux also has decided to modify its European regulatory strategy by withdrawing its application for marketing authorization of Luveniq for the [...]

Isotechnika partner files drug applications

Isotechnika Pharma’s (TSX:ISA) partner, Lux Biosciences, has filed a new drug application with the FDA and a market authorization application with the European Medicines Agency for voclosporin, under the proposed brand name Luveniq. Voclosporin is a next generation calcineurin inhibitor to treat non-infectious uveitis, involving the posterior segment of the eye, a leading cause of [...]